Solid Tumor: Clinical Trials

754 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

284 completed, 168 recruiting, 105 terminated, 104 unknown. 754 Phase 1, 200 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1754Completed 284, Recruiting 168, Terminated 105, Unknown 104, Active not recruiting 54, Not yet recruiting 22, Withdrawn 12, Suspended 3, Enrolling by invitation 2
Phase 2200Recruiting 64, Completed 39, Unknown 30, Terminated 28, Active not recruiting 22, Not yet recruiting 11, Withdrawn 5, Enrolling by invitation 1

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials (filtered) newest first · largest first

All 754 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
4SCAR-276 - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Larotrectinib, Pembrolizumab - Solid Tumor
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center222027-03-012026-09-28
Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors
Chlorine Dioxide Injection 2% - Solid Tumor, Neoplasms
Phase 1Not yet recruitingSunGlow Innovations LLC502027-03-012026-11-02
GD2/PSMA Bi-specific CAR-T Cell Therapy
bi-4SCAR GD2/PSMA T cells - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute602026-12-312026-11-02
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
4SCAR-GD2 - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute102026-12-312026-10-30
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
BON-106 - Solid Tumor, Advanced Solid Tumor
Phase 1Not yet recruitingBeOne Medicines962026-12-012026-10-26
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
[225Ac]Ac-FL-261 - Solid Tumor, NSCLC
Phase 1 / Phase 2RecruitingFull-Life Technologies UK Limited2082026-12-012026-11-16
A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors
BM230 & PD-1 inhibitor - Solid Tumor
Phase 1 / Phase 2Not yet recruitingSuzhou Biomissile Pharmaceuticals Co., Ltd.902026-11-012026-10-09
A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics
HRS-8046 Tablet - Solid Tumor
Phase 1Not yet recruitingChengdu Suncadia Medicine Co., Ltd.1752026-11-012026-11-16
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
HRS-9308 Tablet - Solid Tumor
Phase 1 / Phase 2Not yet recruitingChengdu Suncadia Medicine Co., Ltd.1262026-11-012026-11-16
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Tagmokitug, Pasritamig - Solid Tumor
Phase 1 / Phase 2RecruitingCoherus Oncology, Inc.122026-11-012026-11-18
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
SHR-4595 for Injection - Solid Tumor
Phase 1RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2082026-10-202026-11-02
A Study of DS-3939a in Participants With Solid Tumors
DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingDaiichi Sankyo4002026-10-132026-11-10
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
ASKC189 - Solid Tumor, RAS Mutation
Phase 1Not yet recruitingJiangsu Aosaikang Pharmaceutical Co., Ltd.2002026-09-302026-09-23
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Canagliflozin - Solid Tumor, SGLT 2 Inhibitors
Phase 1RecruitingWest China Hospital152026-09-102026-09-09
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
SI-B036 - Breast Cancer, Solid Tumor
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.392026-08-182026-09-10
A Clinical Study of SHR-4685 on Safety, Tolerability and Pharmacokinetics in Participants With Solid Tumors
SHR-4685 - Solid Tumor
Phase 1RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1702026-08-132026-10-05
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
TJ037130 - Solid Tumor, Metastatic Ovary Cancer
Phase 1RecruitingTJ Biopharma Co., Ltd.1282026-08-052026-10-30
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
SI-B036 - Gastrointestinal Tumor, Solid Tumor
Phase 1RecruitingSichuan Baili Pharmaceutical Co., Ltd.102026-07-302026-09-04
A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors
GS-1206 - Solid Tumor
Phase 1RecruitingGilead Sciences3022026-07-172026-11-04

Showing 20 of 754. Sign in to see all of them.

Narrower conditions

Neoplasms (100)  ·  Neoplasm Metastasis (86)  ·  Carcinoma, Non-Small-Cell Lung (78)  ·  Colorectal Neoplasms (65)  ·  Breast Neoplasms (57)  ·  Melanoma (46)  ·  Stomach Neoplasms (45)  ·  Lymphoma (41)  ·  Ovarian Neoplasms (41)  ·  Pancreatic Neoplasms (40)  ·  Squamous Cell Carcinoma of Head and Neck (31)  ·  Carcinoma, Renal Cell (27)  ·  Endometrial Neoplasms (27)  ·  Lung Neoplasms (27)  ·  Prostatic Neoplasms (23)

Broader conditions

Neoplasms (318)  ·  Neoplasms by Site (283)  ·  Neoplasms by Histologic Type (198)  ·  Digestive System Diseases (140)  ·  Digestive System Neoplasms (137)  ·  Neoplasms, Glandular and Epithelial (117)  ·  Gastrointestinal Diseases (113)  ·  Skin Diseases (111)  ·  Skin and Connective Tissue Diseases (111)  ·  Lung Diseases (108)  ·  Respiratory Tract Diseases (108)  ·  Gastrointestinal Neoplasms (107)  ·  Thoracic Neoplasms (106)  ·  Respiratory Tract Neoplasms (105)  ·  Pathological Conditions, Signs and Symptoms (102)

Interventions

pembrolizumab (60)  ·  Nivolumab (34)  ·  Paclitaxel (24)  ·  Gemcitabine (23)  ·  Cisplatin (22)  ·  Docetaxel (19)  ·  Capecitabine (17)  ·  Injections (16)  ·  Bevacizumab (14)  ·  Carboplatin (13)  ·  Cyclophosphamide (13)  ·  Fluorouracil (13)  ·  Irinotecan (12)  ·  130-nm albumin-bound paclitaxel (11)  ·  atezolizumab (11)

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd. (22)  ·  Eli Lilly and Company (16)  ·  Jiangsu HengRui Medicine Co., Ltd. (13)  ·  M.D. Anderson Cancer Center (11)  ·  Chinese PLA General Hospital (9)  ·  Genentech, Inc. (9)  ·  Impact Therapeutics, Inc. (9)  ·  Merck Sharp & Dohme LLC (9)  ·  Athenex, Inc. (6)  ·  Bristol-Myers Squibb (6)  ·  Hoffmann-La Roche (6)  ·  Innovent Biologics (Suzhou) Co. Ltd. (6)  ·  Memorial Sloan Kettering Cancer Center (6)  ·  Astellas Pharma Inc (5)  ·  Betta Pharmaceuticals Co., Ltd. (5)

Countries

United States (381)  ·  China (234)  ·  Spain (55)  ·  South Korea (54)  ·  Australia (51)  ·  France (48)  ·  United Kingdom (39)  ·  Japan (38)  ·  Canada (33)  ·  Belgium (21)  ·  Taiwan (21)  ·  Netherlands (19)  ·  Italy (16)  ·  Germany (15)  ·  Israel (12)

Top investigators

David Cutler, MD (5)  ·  Jian Zhang (4)  ·  Chuanling Li (3)  ·  Jian Zhang, Doctor (3)  ·  Jin Li (3)

Results publications

PMID 38172595, PMID 29505699, PMID 35101941, PMID 37082579, PMID 37592303, PMID 42413526, PMID 42636835, PMID 18463792, PMID 19139178, PMID 20305636, PMID 21810918, PMID 22382879, PMID 22415795, PMID 23615181, PMID 24173967, PMID 24349470, PMID 24477603, PMID 24523121, PMID 24819685, PMID 25086465, PMID 25380636, PMID 26172205, PMID 26222558, PMID 26390038, PMID 26942463, PMID 26966027, PMID 26984449, PMID 27000274, PMID 27053773, PMID 27138582, PMID 27157491, PMID 27240885, PMID 27247226, PMID 27565932, PMID 27627808, PMID 27646946, PMID 27871319, PMID 28081914, PMID 28196905, PMID 28291584, PMID 28387632, PMID 28453692, PMID 28465370, PMID 28489510, PMID 28630120, PMID 28813164, PMID 28837405, PMID 28972963, PMID 29095678, PMID 29116900

NIH funding

2023 (12), 2018 (8), 2015 (6), 2016 (6), 2019 (6), 2014 (4), 2017 (3), 2008 (2), 2025 (1), P01CA111412 (1), R01CA266666 (1), R01MH115043 (1), R44CA265656 (1)